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Introduction
MASIF (Medication Adherence Scale in FMF) is an instru-
ment designed to measure adherence to treatment in
children with Familial Mediterranean Fever (FMF). We
have developed this scale for children with FMF and
found valid and reliable.
Objectives
In this study, it was aimed to assess the validity and relia-
bility of this adherence scale for medical treatment in
adult FMF patients.
Methods
This study is multicentre and 14 centers participated to
the study. Patients with FMF using medication at least for
6 months and accepted to participate constituted the sam-
ple of the study. Besides “Medication Adherence Scale in
FMF Patients (MASIF)”, “Data collection forms about the
sociodemographic and medical information (demographic,
clinical and laboratory findings) of patients”, and “Morisky
Medication Adherence Scale (MMAS)” were used as data
collection instruments.
Results
There were 133 patients with FMF enrolled for the valida-
tion of the study. The median age of the patients (n=133)
was 28.60 years (min.18.12-max.71.34) and 52.6% of them
were female. The median number of the attack frequency
was 13.50 (min. 0-max 99) in a year and 57.9% of the par-
ticipants had irregular attacks. For internal consistency,
Cronbach’s alpha was 0,764 for MASIF adult version.
Also, there was a positive and significant correlation
between test and retest score (t=0.971; p=0.340). Morisky
was used as gold standard. For the “criterion validity” the
correlation with Morisky and MASIF was evaluated
(r=0.530, p=0.000) and for the “structure” validity, factor
analyzes and Kaiser-Meyer-Olkin tests were performed.
Conclusion
Approximately 10-15% of patients with FMF are non-
responders but it was claimed that in fact they are non-
compliers that causes these patients receive unnecessary
biologic agent treatment procedures, which are hazardous
as well as expensive. This scale will provide assessment
and follow up of adherence to treatment patients and
determine whether the patient is non-responders or non-
compliers. It may help to determine the non-compliance
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